Comparative Pharmacology
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus LYBALVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus LYBALVI.
DAPIPRAZOLE HYDROCHLORIDE vs LYBALVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
5 mg orally once daily, titrated as needed up to 10 mg once daily.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment
Terminal half-life ~20-30 hours; supports once-daily dosing.
Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%)
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic